Ranbaxy Lab shoots up on registering 4-folds increase in Q1CY12 consolidated net profit

Ranbaxy Laboratories Ltd.- (Amalgamation) | Pharmaceuticals & Drugs | Healthcare | BSE: 500359 | NSE: RANBAXY

09 May 2012 Evaluate

Drug maker Ranbaxy Laboratories has reported higher than expected profit for the quarter ended March 31, 2012

The Company has posted a net profit of Rs 827.23 crore for Q1 CY12 as compared to net loss of Rs 52.90 crore for theQ1CY11. Company’s total income has increased by 72.26% to Rs 2050.11 crore for the quarter as compared to Rs 1190.14 crore for the similar quarter of previous fiscal.

On consolidated basis, group’s net profit after tax, minority interest and share of profit of associates zoomed by 309.59% at Rs 1246.76 crore for the January-March quarter as compared to Rs 304.39 crore for the similar quarter a period ago. Group’s total income has risen by 71.84% to Rs 3923.47 crore for the quarter under review from Rs 2283.19 crore for the quarter ended March 31, 2011.

Ranbaxy Laboratories is currently trading at Rs 514.10, up by 20.40 points or 4.13% from its previous closing of Rs 493.70 on the BSE.

The scrip opened at Rs 498.15 and has touched a high and low of Rs 517.75 and Rs 492.65 respectively. So far 505010 shares were traded on the counter.

The BSE group 'A' stock of face value Rs 5 has touched a 52 week high of Rs 570.00 on 02-Aug-2011 and a 52 week low of Rs 366.50 on 19-Dec-2011.

Last one week high and low of the scrip stood at Rs 517.75 and Rs 491.10 respectively. The current market cap of the company is Rs 21766.24 crore.

The promoters holding in the company stood at 63.67% while Institutions and Non-Institutions held 20.47% and 13.82% respectively.

The estimates were that the group would report a growth of 34% year-on-year in its profit after tax at Rs 408 crore for the first quarter of CY12.

As of March 2012, Ranbaxy had 45% market share in the Lipitor generic market. In Q4, Lipitor generic contributed $300 million to revenues and market share was 42% with price erosion of 65%.

Ranbaxy Labs. Share Price

Not Listed

View Price Chart

Peers

Company Name	CMP
Sun Pharma Inds.	1851.95
Dr. Reddys Lab	1288.55
Cipla	1408.00
Zydus Lifesciences	1067.95
Lupin	2349.05
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Fiduciary-first advisory model.
As SEBI-registered IAs, we are legally and ethically bound to act in the best interests of our clients. We do not sell or distribute any financial products. This ensures our guidance is 100% unbiased and conflict-free.
Deep fundamental research + robust valuation discipline.
Built on more than 15 years of equity research, our framework combines quality assessment, intrinsic value estimation, and a sensible margin-of-safety approach.
Process—not predictions.
We don’t rely on guesswork or market timing. Instead, we focus on asset allocation, risk management, and long-term compounding.
Technology + Human Intelligence.
We believe a combination of both is essential for investing success. We constantly innovate and upgrade in-house tools, financial X-rays, and portfolio analytics so that our team of analysts and advisors are equipped with the best.
Partner with Clients.
We follow a DIWM (Do-It-With-Me) approach where we partner clients in setting goals, financial planning, educating on our investing process and share decision-enabling resources transparently with our clients who retain control on execution.

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

Investing in stocks, mutual funds, debt, and gold
Quality-at-Reasonable-Price way of investing in stocks
Constructing Direct Stock Portfolios with Core, Booster, and Amplifier stocks
A Mutual Fund Portfolio that delivers consistent out-performance and meaningful diversification (low overlap)
Periodic review and rebalancing
Clear Buy-Sell-Hold, and Position-sizing frameworks

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.